Amgen sues Sandoz to block biosimilar of blockbuster bone drug

Amgen is suing Sandoz in federal court over the company’s plan to seek FDA approval of a biosimilar version of denosumab, alleging 42 instances of patent infringement for the blockbuster biologic. The complaint, filed Monday in New Jersey, names Sandoz, its subsidiary Lek Pharmaceuticals, and its parent company Novartis. The…